PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development of technologies and novel therapies through its photochemical technology platform. The company's technology platform consists of a proprietary small molecule photosensitiser and a light source; and develops photochemical lysis (PCL) comprising light-triggered cell lysis, which enhances yield and purity in viral vector manufacturing, as well as photochemical internalisation (PCI), inducing light-triggered intracellular release for various therapeutic modalities. It also explores for intratumoural immunotherapy therapeutics that identifies novel treatment combinations to overcome resistance to immune-checkpoint inhibitors and safety-issues associated with treatments; and develops nucleic acid therapeutics to improve the treatment of dermatological diseases. PCI Biotech Holding ASA was incorporated in 2007 and is headquartered in Oslo, Norway.
Frequently asked questions
What sector does PCI Biotech Holding ASA (PCIB) operate in?
PCI Biotech Holding ASA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is PCI Biotech Holding ASA (PCIB) current stock price?
As of the latest data, PCI Biotech Holding ASA stock price is NOK 0.07, with a previous close of NOK 0.07.
What is PCI Biotech Holding ASA (PCIB) current market capitalization?
PCI Biotech Holding ASA market cap is approximately 2.61 million.
What is PCI Biotech Holding ASA (PCIB) Earnings Per Share (EPS)?
The trailing EPS is -NOK 0.55.
Does PCI Biotech Holding ASA (PCIB) pay dividends?
No. PCI Biotech Holding ASA does not pay a dividend.
When is PCI Biotech Holding ASA (PCIB) next earnings report?
PCI Biotech Holding ASA is expected to release its next earnings report on June 30, 2026.
What is PCI Biotech Holding ASA (PCIB) beta (volatility) score?
PCI Biotech Holding ASA has a beta of 0.794, indicating lower volatility than the overall market.
